Please login to the form below

Not currently logged in
Email:
Password:

Dutch biotech Mucosis promotes Thomas Johnston to CEO

He succeeds Govert Schouten who leaves to found an internet start-up

Dutch biotech Mucosis Thomas JohnstonThomas Johnston has been promoted to CEO of Mucosis to take over from Govert Schouten, who is leaving the Dutch clinical-stage biotech to found an internet start-up.

Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.

Prior to that he served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with companies such as Comcast, Microsoft, and Schlumberger.

John Lambert, chairman of the Mucosis board of directors, said: "Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team.

“Given Tom's substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialisation of the Mimopath platform including our RSV vaccine candidate."

During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.

19th September 2012

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...